NAYA Biosciences, Inc Total Liabilities
NAYA Biosciences, Inc total liabilities. Based on the latest financial reports, NAYA Biosciences, Inc (NAYA) has total liabilities worth $33.70 Million USD as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See NAYA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of NAYA Biosciences, Inc (2007–2024)
Total liabilities of NAYA Biosciences, Inc from 2007 to 2024. This chart illustrates how NAYA Biosciences, Inc's total liabilities have evolved over time, based on quarterly financial data. Explore NAYA Biosciences, Inc (NAYA) long-term investment share to see how much of total assets are deployed in long-term investments.
NAYA Biosciences, Inc Competitors by Total Liabilities
The table below lists competitors of NAYA Biosciences, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Richmond Minerals Inc
V:RMD
|
Canada | CA$362.96K |
|
Fjordland Exploration Inc
V:FEX
|
Canada | CA$125.33K |
|
Lexus Granito (India) Limited
NSE:LEXUS
|
India | Rs-182.41 Million |
|
Gulf Marine Services PLC
LSE:GMS
|
UK | GBX263.39 Million |
|
China Pharma Holdings Inc
NYSE MKT:CPHI
|
USA | $7.49 Million |
|
Halo Technologies Holdings Ltd
AU:HAL
|
Australia | AU$408.41 Million |
|
PolyPlank publ AB
ST:POLY
|
Sweden | Skr21.55 Million |
|
Lavide Holding NV
AS:LVIDE
|
Netherlands | €591.86K |
Liability Composition Analysis (2007–2024)
This chart breaks down NAYA Biosciences, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NAYA asset base.
Liquidity & Leverage Metrics
NAYA Biosciences, Inc Total Liabilities Ratios Explained
NAYA Biosciences, Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NAYA Biosciences, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NAYA Biosciences, Inc (2007–2024)
The table below shows the annual total liabilities of NAYA Biosciences, Inc from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.70 Million | +91.34% |
| 2023-12-31 | $17.61 Million | +275.76% |
| 2022-12-31 | $4.69 Million | +48.54% |
| 2021-12-31 | $3.16 Million | -39.36% |
| 2020-12-31 | $5.20 Million | -5.53% |
| 2019-12-31 | $5.51 Million | +57.33% |
| 2018-12-31 | $3.50 Million | -33.41% |
| 2017-12-31 | $5.26 Million | +7.23% |
| 2016-12-31 | $4.90 Million | +13.08% |
| 2015-12-31 | $4.34 Million | +62.86% |
| 2010-12-31 | $2.66 Million | -24.46% |
| 2009-12-31 | $3.52 Million | +256.73% |
| 2008-12-31 | $988.12K | +530.59% |
| 2007-12-31 | $156.70K | -- |
About NAYA Biosciences, Inc
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as soli… Read more